SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:umu-156420"
 

Sökning: id:"swepub:oai:DiVA.org:umu-156420" > Immune marker chang...

Immune marker changes and risk of multiple myeloma : a nested case-control study using repeated prediagnostic blood samples

Späth, Florentin, 1980- (författare)
Umeå universitet,Onkologi,Melin
Wibom, Carl (författare)
Umeå universitet,Onkologi,Melin
Krop, Esmeralda (författare)
Utrecht University
visa fler...
Izarra Santamaria, Antonio (författare)
Umeå universitet,Onkologi
Johansson, Ann Sofie (författare)
Umeå universitet,Onkologi
Bergdahl, Ingvar (författare)
Umeå universitet,Enheten för biobanksforskning
Hultdin, Johan (författare)
Umeå universitet,Klinisk kemi
Vermeulen, Roel (författare)
Utrecht University
Melin, Beatrice S. (författare)
Umeå universitet,Onkologi,Melin
visa färre...
 (creator_code:org_t)
2019-04-04
2019
Engelska.
Ingår i: Haematologica. - : Ferrata Storti Foundation. - 0390-6078 .- 1592-8721. ; 104:12, s. 2456-2464
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Biomarkers reliably predicting progression to multiple myeloma (MM) are lacking. Myeloma risk has been associated with low blood levels of monocyte chemotactic protein-3 (MCP-3), macrophage inflammatory protein-1 alpha (MIP-1 alpha), vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), fractalkine, and transforming growth factor-alpha (TGF-alpha). In this study, we aimed to replicate these findings and study the individual dynamics of each marker in a prospective longitudinal cohort, thereby examining their potential as markers of myeloma progression. For this purpose, we identified 65 myeloma cases and 65 matched cancer-free controls each with two donated blood samples within the Northern Sweden Health and Disease Study. The first and repeated samples from myeloma cases were donated at a median 13 and 4 years, respectively, before the myeloma was diagnosed. Known risk factors for progression were determined by protein-, and immunofixation electrophoresis, and free light chain assays. We observed lower levels of MCP-3, VEGF, FGF-2, and TGF-alpha in myeloma patients than in controls, consistent with previous data. We also observed that these markers decreased among future myeloma patients while remaining stable in controls. Decreasing trajectories were noted for TGF-alpha (P=2.5 x 10(-4)) indicating progression to MM. Investigating this, we found that low levels of TGF-alpha assessed at the time of the repeated sample were independently associated with risk of progression in a multivariable model (hazard ratio = 3.5; P=0.003). TGF-alpha can potentially improve early detection of MM.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

prospective longitudinal study
multiple myeloma risk
progression
marker trajectories
onkologi
Oncology
Cancer Epidemiology
cancerepidemiologi

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy